PDF(Pubmed)
Abstract：
Cancer immunotherapy has shown remarkable clinical progress in recent years. Although age is one of the biggest leading risk factors for cancer development and older adults represent a majority of cancer patients, only a few new cancer immunotherapeutic interventions have been preclinically tested in aged animals. Thus, the lack of preclinical studies focused on age-dependent effect during cancer immunotherapy could lead to different therapeutic outcomes in young and aged animals and future modifications of human clinical trials. Here, we compare the efficacy of previously developed and tested intratumoral immunotherapy, based on the combination of polysaccharide mannan, toll-like receptor ligands, and anti-CD40 antibody (MBTA immunotherapy), in young (6 weeks) and aged (71 weeks) mice bearing experimental pheochromocytoma (PHEO). The presented results point out that despite faster growth of PHEO in aged mice MBTA intratumoral immunotherapy is effective approach without age dependence and could be one of the possible therapeutic interventions to enhance immune response to pheochromocytoma and perhaps other tumor types in aged and young hosts.
摘要：
近年来，肿瘤免疫治疗在临床上取得了显著进展。尽管年龄是癌症发展的最大主要风险因素之一，老年人代表了大多数癌症患者，只有少数新的癌症免疫治疗干预措施在老年动物中进行了临床前测试.因此，缺乏关注癌症免疫治疗过程中年龄依赖性效应的临床前研究,可能会导致幼年和老年动物的治疗结果不同,并且未来会对人体临床试验进行修改.这里,我们比较了以前开发和测试的肿瘤内免疫疗法的疗效，基于多糖甘露聚糖的组合，toll样受体配体，和抗CD40抗体（MBTA免疫治疗），在患有实验性嗜铬细胞瘤（PHEO）的年轻（6周）和老年（71周）小鼠中。所提出的结果指出，尽管PHEO在老年小鼠中生长更快，但MBTA肿瘤内免疫疗法是没有年龄依赖性的有效方法，并且可能是增强老年和年轻宿主对嗜铬细胞瘤和其他肿瘤类型的免疫反应的可能治疗干预措施之一。
